Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
CareDx reported strong growth for 2025 while reshaping its leadership team. Full-year revenue reached $380 million, up 14% from 2024, with Q4 revenue of $108 million, up 25%. Testing services, patient and digital solutions, and product revenue all grew double‑digits.
The company posted a 2025 GAAP net loss of $21 million, but delivered non‑GAAP net income of $32 million and adjusted EBITDA of $32 million. Cash, cash equivalents and marketable securities were about $201 million as of December 31, 2025 after $88 million of share repurchases. For 2026, CareDx guides revenue to $420–$444 million and adjusted EBITDA of $30–$45 million.
The Board appointed Keith Kennedy as Chief Financial Officer and Chief Operating Officer, effective February 26, 2026, following the resignation of CFO Nathan Smith for personal reasons. Smith will receive severance including nine months’ salary, a $91,643 bonus, COBRA premium reimbursement for nine months, and vesting of 5,840 restricted stock units.
CareDx reported strong growth for 2025 while reshaping its leadership team. Full-year revenue reached $380 million, up 14% from 2024, with Q4 revenue of $108 million, up 25%. Testing services, patient and digital solutions, and product revenue all grew double‑digits.
The company posted a 2025 GAAP net loss of $21 million, but delivered non‑GAAP net income of $32 million and adjusted EBITDA of $32 million. Cash, cash equivalents and marketable securities were about $201 million as of December 31, 2025 after $88 million of share repurchases. For 2026, CareDx guides revenue to $420–$444 million and adjusted EBITDA of $30–$45 million.
The Board appointed Keith Kennedy as Chief Financial Officer and Chief Operating Officer, effective February 26, 2026, following the resignation of CFO Nathan Smith for personal reasons. Smith will receive severance including nine months’ salary, a $91,643 bonus, COBRA premium reimbursement for nine months, and vesting of 5,840 restricted stock units.
CareDx, Inc. (CDNA) received an updated ownership report on its common stock from investment manager Neil Gagnon and related entities. As of the reported date, Gagnon reports beneficial ownership of 3,054,946 shares of CareDx common stock, representing 5.9% of the class.
Within this total, Gagnon Securities LLC reports beneficial ownership of 2,213,827 shares, or 4.3% of the class, and Gagnon Advisors, LLC reports 532,892 shares, or 1.0%. The filing states the securities are not held for the purpose of changing or influencing control of CareDx.
State Street Corporation has filed a Schedule 13G reporting a passive ownership stake in CareDx, Inc. (CDNA). As of 12/31/2025, State Street reports beneficial ownership of 2,737,752 shares of CareDx common stock, representing 5.3% of the outstanding class.
State Street reports shared voting power over 2,606,232 shares and shared dispositive power over 2,737,752 shares, with no sole voting or dispositive power. The position is held through investment management affiliates, including SSGA Funds Management and various State Street Global Advisors entities, and is certified as being held in the ordinary course of business without the purpose of influencing control.
CareDx Chief Operating Officer Kennedy Keith reported equity compensation and related tax withholding transactions in company common stock. On February 2, 2026, Keith received 60,000 shares represented by restricted stock units at $0 per share, which will vest over three years starting April 6, 2027. Keith also acquired 14,474 shares from performance-based restricted stock units that were earned after performance goals were certified on February 2, 2026. To cover tax obligations from the PRSU vesting, 4,644 shares were withheld at a price of $20.42 per share. After these transactions, Keith directly owns 209,139 CareDx common shares.
CareDx, Inc. Chief Commercial Officer Jessica Meng reported equity awards and a related tax withholding transaction. On February 2, 2026, she was granted 60,000 restricted stock units (RSUs), which vest one-third on April 6, 2027 and the remaining two-thirds in eight equal quarterly installments so that all RSUs vest by the third anniversary of April 6, 2027, subject to continuous employment. She also earned 11,579 shares from a performance restricted stock unit (PRSU) award initially granted on February 1, 2025, after performance criteria were certified on February 2, 2026. In connection with the PRSU vesting, 4,430 shares of common stock were withheld at $20.42 per share to satisfy tax withholding obligations, leaving her with 176,778 directly held common shares.
CareDx, Inc. Chief Financial Officer Nathan Smith reported equity compensation and related tax withholding transactions. On February 2, 2026 he was granted 33,000 restricted stock units, which will vest in stages beginning April 6, 2027 and fully vest three years after that date, subject to continued employment.
He also acquired 7,875 common shares at no cost from a performance RSU award that was originally granted on February 1, 2025 and earned after performance goals were certified on February 2, 2026. To cover tax withholding on the PRSU vesting, 3,859 shares were withheld at a price of $20.42 per share, leaving him with 79,016 directly owned shares.
CareDx, Inc. Secretary and General Counsel Jeffrey Adam Novack reported multiple equity transactions in company common stock. He was granted 33,000 restricted stock units that begin vesting on April 6, 2027 over three years, subject to continued employment, and 4,342 shares from a performance RSU award earned after performance criteria were certified on February 2, 2026. To cover tax withholding on PRSU and RSU vesting, 2,492 and 2,970 shares, respectively, were withheld by CareDx. On February 3, 2026, 4,441 shares were sold at $20.5553 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Novack directly held 125,364 shares of CareDx common stock.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported equity compensation and related tax withholding transactions. On February 2, 2026, he was granted 162,500 restricted stock units (RSUs) at $0 per share. One-third of these RSUs will vest on April 6, 2027, with the remaining two-thirds vesting in equal quarterly installments over the following eight quarters, so that all RSUs vest by the third anniversary of April 6, 2027, subject to continued employment.
He also acquired 37,632 shares of common stock at $0 per share, earned from a performance restricted stock unit (PRSU) award initially granted on February 1, 2025, after performance criteria were certified on February 2, 2026. To cover tax withholding on the PRSU vesting, 13,694 shares were withheld at a price of $20.42 per share. After these transactions, he directly owned 783,843 shares of CareDx common stock.
CareDx, Inc. insider Jeffrey Novack has filed a Form 144 notice to sell company stock. The filing covers a proposed sale of 4,441 shares of CareDx common stock through Morgan Stanley Smith Barney LLC on the NASDAQ market, with an aggregate market value of $90,685.22 and 51,432,639 shares of common stock outstanding.
The shares to be sold were acquired on 02/01/2026 via 2,591 restricted stock units and 1,850 performance stock units from the issuer, both settled on 02/01/2026. Over the past three months, Form 144 discloses additional 10b5-1 sales for Jeffrey Novack totaling 7,293 shares on 12/04/2025 and 2,688 shares on 11/07/2025, with gross proceeds of $139,804.74 and $41,722.87, respectively.
CareDx, Inc. President and CEO John Walter Hanna Jr., who is also a director, reported open-market sales of the company’s common stock. On January 21, 2026, he sold 200 shares at $21.00 per share, and on January 22, 2026, he sold 19,280 shares at a weighted average price of $21.163 per share. These transactions were coded as open market sales and were made under a Rule 10b5-1 trading plan adopted on December 13, 2024. Following the later transaction, he beneficially owned 597,405 shares of CareDx common stock directly.